Tags

Type your tag names separated by a space and hit enter

Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.
Front Oncol 2019; 9:943FO

Abstract

Although significant progress has been made in the implementation of new breast cancer treatments over the last three decades, this neoplasm annually continues to show high worldwide rates of morbidity and mortality. In consequence, the search for novel therapies with greater effectiveness and specificity has not come to a stop. Among the alternative therapeutic targets, the human gonadotropin-releasing hormone type I and type II (hGnRH-I and hGnRH-II, respectively) and its receptor, the human gonadotropin-releasing hormone receptor type I (hGnRHR-I), have shown to be powerful therapeutic targets to decrease the adverse effects of this disease. In the present review, we describe how the administration of GnRH analogs is able to reduce circulating concentrations of estrogen in premenopausal women through their action on the hypothalamus-pituitary-ovarian axis, consequently reducing the growth of breast tumors and disease recurrence. Also, it has been mentioned that, regardless of the suppression of synthesis and secretion of ovarian steroids, GnRH agonists exert direct anticancer action, such as the reduction of tumor growth and cell invasion. In addition, we discuss the effects on breast cancer of the hGnRH-I and hGnRH-II agonist and antagonist, non-peptide GnRH antagonists, and cytotoxic analogs of GnRH and their implication as novel adjuvant therapies as antitumor agents for reducing the adverse effects of breast cancer. In conclusion, we suggest that the hGnRH/hGnRHR system is a promising target for pharmaceutical development in the treatment of breast cancer, especially for the treatment of advanced states of this disease.

Authors+Show Affiliations

Unidad de Investigación Médica en Enfermedades Nefrológicas, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Hospital de Especialidades, Mexico City, Mexico.Unidad de Investigación Médica en Medicina Reproductiva, IMSS, Unidad Médica de Alta Especialidad No. 4, Mexico City, Mexico.Unidad de Investigación Médica en Medicina Reproductiva, IMSS, Unidad Médica de Alta Especialidad No. 4, Mexico City, Mexico.Unidad de Investigación Médica en Medicina Reproductiva, IMSS, Unidad Médica de Alta Especialidad No. 4, Mexico City, Mexico.Centre National de la Recherche Scientifique, CNRS-ERL9195, Paris, France.Unité d'Analyse d'Images Biologiques, Institut Pasteur, Paris, France. Centre National de la Recherche Scientifique, CNRS-UMR3691, Paris, France.Unidad de Investigación Médica en Medicina Reproductiva, IMSS, Unidad Médica de Alta Especialidad No. 4, Mexico City, Mexico. Unité d'Analyse d'Images Biologiques, Institut Pasteur, Paris, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31632902

Citation

Huerta-Reyes, Maira, et al. "Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs." Frontiers in Oncology, vol. 9, 2019, p. 943.
Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, et al. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019;9:943.
Huerta-Reyes, M., Maya-Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo-Marin, J. C., & Aguilar-Rojas, A. (2019). Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Frontiers in Oncology, 9, p. 943. doi:10.3389/fonc.2019.00943.
Huerta-Reyes M, et al. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019;9:943. PubMed PMID: 31632902.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. AU - Huerta-Reyes,Maira, AU - Maya-Núñez,Guadalupe, AU - Pérez-Solis,Marco Allán, AU - López-Muñoz,Eunice, AU - Guillén,Nancy, AU - Olivo-Marin,Jean-Christophe, AU - Aguilar-Rojas,Arturo, Y1 - 2019/10/01/ PY - 2019/07/16/received PY - 2019/09/09/accepted PY - 2019/10/22/entrez PY - 2019/10/22/pubmed PY - 2019/10/22/medline KW - GnRH agonist KW - GnRH analogs KW - GnRH antagonist KW - breast cancer KW - breast cancer adjuvant therapy KW - gonadotropin-releasing hormone (GnRH) KW - gonadotropin-releasing hormone receptor (GnRHR) SP - 943 EP - 943 JF - Frontiers in oncology JO - Front Oncol VL - 9 N2 - Although significant progress has been made in the implementation of new breast cancer treatments over the last three decades, this neoplasm annually continues to show high worldwide rates of morbidity and mortality. In consequence, the search for novel therapies with greater effectiveness and specificity has not come to a stop. Among the alternative therapeutic targets, the human gonadotropin-releasing hormone type I and type II (hGnRH-I and hGnRH-II, respectively) and its receptor, the human gonadotropin-releasing hormone receptor type I (hGnRHR-I), have shown to be powerful therapeutic targets to decrease the adverse effects of this disease. In the present review, we describe how the administration of GnRH analogs is able to reduce circulating concentrations of estrogen in premenopausal women through their action on the hypothalamus-pituitary-ovarian axis, consequently reducing the growth of breast tumors and disease recurrence. Also, it has been mentioned that, regardless of the suppression of synthesis and secretion of ovarian steroids, GnRH agonists exert direct anticancer action, such as the reduction of tumor growth and cell invasion. In addition, we discuss the effects on breast cancer of the hGnRH-I and hGnRH-II agonist and antagonist, non-peptide GnRH antagonists, and cytotoxic analogs of GnRH and their implication as novel adjuvant therapies as antitumor agents for reducing the adverse effects of breast cancer. In conclusion, we suggest that the hGnRH/hGnRHR system is a promising target for pharmaceutical development in the treatment of breast cancer, especially for the treatment of advanced states of this disease. SN - 2234-943X UR - https://www.unboundmedicine.com/medline/citation/31632902/Treatment_of_Breast_Cancer_With_Gonadotropin-Releasing_Hormone_Analogs L2 - https://doi.org/10.3389/fonc.2019.00943 DB - PRIME DP - Unbound Medicine ER -